Genetic Testing Market

Genetic Testing Market by Type (Carrier Testing, Diagnostic Testing, New-Born Screening, Predictive & Pre-Symptomatic Testing, Prenatal Testing), by Technology (Cytogenetic Testing, Molecular Testing, Biochemical Testing), by Clinical Indication (Alzheimer’s Disease, Cancer, Cystic Fibrosis, Sickle Cell Anaemia, Duchenne’s Muscular Dystrophy, Thalassemia, Huntington’s Disease), by Geography (U.S., Canada, Germany, U.K., France, Italy, Spain, Japan, China, India, Brazil, Mexico) – Global Market Size, Share, Development, Growth and Demand Forecast, 2013-2023

Delivery : 24-72 Working Hours
Report Code: LS11364
Available Format:
Category : Biotechnology

Genetic Testing Market Overview

The global genetic testing market is projected to grow considerably in the coming years, due to the growing number of test to study multiple genes that may help in managing individual health condition. Additionally, the government initiatives to spread awareness with respect to the advantages of procedure is further expected to drive the growth of the market. The market is categorized into carrier testing, diagnostic testing, new-born screening, predictive & pre-symptomatic testing, prenatal testing, based on types of gene testing. Among the various types, new born screening held the largest share in 2016, due to the growing number of newborn genetic screening programs, while carrier testing is expected to project the fastest growth in demand during the forecast period.

The different technologies used for genetic testing include cytogenetic testing, molecular testing, and biochemical testing. Molecular testing was the most widely utilized technology used for testing and analysis of genes, and held the largest share in the global market, in 2016. This leading position of the category is mainly attributable to the increasing analysis on the biological markers in the genome and proteome studies.

The genetic testing market has been bifurcated into Alzheimer's disease, cancer, cystic fibrosis, sickle cell anaemia, Duchenne's muscular dystrophy, thalassemia, and Huntington’s disease and others, based on clinical indication. Among the various clinical indications, cancer testing occupied the largest share of the genetic testing market in 2016, owing to the increasing prevalence of cancer, and rising awareness about the early diagnosis of the diseases.

North America was the largest contributor to the market in 2016. According to the NCBI repository that maintains Genetic Testing Registry(GTR)data from 505 lab participants worldwide, the U.S. leads with 259 labs contributions. Some of the key factors leading to the growth of the market in the region are the presence of large number of academic and research institutes, rising government funding, and availability of technologically advanced products. However, Asia-Pacific is expected to witness the fastest growth in the genetic testing market during the forecast period. The major factors driving the region’s growth include increasing awareness about the advantages of predictive testing, and rise in the adoption of advanced technology for clinical applications.

Genetic Testing Market Dynamics

Growth Drivers

Increasing application of the gene testing in oncological research, rising incidences of genetic disorders, technological advancements and rising demand for personalized medicine are the major drivers augmenting the growth of the genetic testing industry.

According to the WHO, sickle cell anemia is one of the genetic disorders particularly common among people whose ancestors come from Sub-Saharan Africa, South America, Cuba, Central America, Saudi Arabia, India, and Mediterranean countries such as Turkey, Greece, and Italy. However, high cost involves in gene testing, and lack of the experienced professionals are the key factors hampering the growth of the genetic testing market.


Genetic tests in conjugation with other genomic technologies would help predict the risk of an individual to a disease and is also expected to assist clinicians to select suitable therapeutic interventions. These factors also increase the opportunities for players in pharmaceutical industry to grow, by providing treatment options to their end users. For instance, 23andMe offers direct genetic makeup tests to the consumers and based on the results of tests, the company recommends genetic counsellors to help the consumers about the better testing of genes, and the inherited diseases.

Genetic Testing Market Competitive Landscape

Major players in the genetic testing market are Transgenomic, Inc., GE Healthcare, 23 & Me Sequenom, Inc., Abbott Laboratories, Biocartis SA, Illumina Inc., 454 Life Sciences, Bio-Rad Laboratories, Luminex Corporation, Affymetrix Inc., Agilent Technologies Inc., Cephide Inc., Beckman Coulter Inc.

With respect to strategic developments, various new product launches and strategic alliances have been taking place in the genetic testing industry.

In November 2016, Biocartis SA entered into a partnership with Thermo Fisher Scientific Inc. to distribute its Idylla platform and accompanying assays, with a first focus on oncology products in the U.S. In February 2016, Biocartis SA collaborated with Amgen Inc. to evaluate the Idylla RAS testing as a tool for rapid decentralized testing in a range of countries. This collaboration was expanded in December 2016 to include 10 new European countries and expected to enable additional selected hospitals to accelerate patient access to RAS biomarker information using Biocartis’ Idylla platform and RAS tests.

Genetic Testing Market Segmentation

By Type

  • Carrier Testing
  • Diagnostic Testing
  • New-born Screening
  • Predictive and Pre-Symptomatic Testing
  • Prenatal Testing

By Technology

  • Cytogenetic Testing
  • Molecular Testing
  • Biochemical Testing

By Clinical Indication

  • Alzheimer's Disease
  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anaemia
  • Duchenne's Muscular Dystrophy
  • Thalassemia
  • Huntington’s Disease
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (MEA)

Place An Order

Single User License

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry